Stem Cell Therapy Market - By Type (Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Oncology, Orthopedic, Cardiovascular, Neurology), End-use (Hospitals, Clinics) & Global Forecast, 2023-2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationStem Cell Therapy Market - By Type (Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Oncology, Orthopedic, Cardiovascular, Neurology), End-use (Hospitals, Clinics) & Global Forecast, 2023-2032
Stem Cell Therapy Market Size
Stem Cell Therapy Market size was valued at over USD 11.8 billion in 2022. Driven by the increasing occurrence of chronic ailments across the globe, the market is anticipated to grow at over 10% CAGR from 2023 to 2032.
Increasing incidence of chronic disorders such as muscular dystrophy, neurological ailments, cancer, and others in both developed and developing economies is proliferating the demand for advanced experimental medical treatment. The US reported over 608,570 deaths due to cancer and nearly 1.9 million newly diagnosed cases of the disease in 2021 alone. Such high case loads are creating a notable impetus for stem cell-based therapy, fostering stem cell therapy market progress.
Over time, conventional drugs and treatments have demonstrated an efficacy drop when treating chronic ailments such as cancer. Stem cell-based therapies, although still considered experimental, are regarded highly promising when it comes to treating such ailments. In fact, treatments such as mesenchymal stem cell therapy have been proven efficacious in treating inflammatory, degenerative, and autoimmune disorders due to their regenerative potential and immunoregulatory properties.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Stem Cell Therapy Market Size in 2022 | USD 11.8 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 10% |
| 2032 Value Projection | USD 31.5 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 120 |
| Tables, Charts & Figures | 241 |
| Segments covered | Type, Therapeutic area, End-use, and Region |
| Growth Drivers | |
| Pitfalls & Challenges |
Ethical considerations in stem cell therapy may constrain industry development
Even though more people are using stem cell treatments, the ethical issues that come with them might slow down the growth of the market. Right now, there's a lot of debate about where pluripotent stem cell lines come from, whether it's from eggs or embryos. Some stem cell treatments have risks, like the patient's immune system rejecting the cells used in the treatment. Other risks of stem cell transplants include the cells moving to the wrong places in the body and tumors forming. Also, because of the medical risks that come with getting eggs and other problems with experimental treatments, not as many people want these therapies.
Stem Cell Therapy Market Analysis
Based on therapeutic area, stem cell therapy market from orthopedic segment is expected to grow at over 9.5% CAGR from 2023 to 2032, fueled by the surging occurrence of orthopedic ailments among the elderly population. Therapeutic or treatment procedures that incorporate stem cells are believed to have the potential to facilitate faster healing of bone and cartilage defects. These regenerative therapies work for various orthopedic complications such as osteoarthritis, focal and cartilage damage among others, and effectively eliminate the need for invasive surgeries where the geriatric population have a historically low success and survival rate.
Stem cell therapy is getting a big boost in hospitals, with over $6.5 billion spent in 2022. That's because governments are investing heavily in improving healthcare for everyone. For example, in October 2022, the US government put up $110 million to make healthcare more accessible in rural areas. A lot of that money will be used to build new hospitals. And hospitals that work with universities and research centers are major players in stem cell therapy research and development. This helps hospitals push the boundaries of stem cell treatments.
Stem cell treatments are becoming increasingly popular in Europe, and the market is expected to grow to over $8 billion by 2032. This growth is being driven by the rise in neurodegenerative diseases, such as Alzheimer's and Parkinson's, which are currently incurable. Stem cells have the ability to develop into any type of cell in the body, and they have shown promising results in treating neurodegenerative diseases. For example, mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs) have been shown to improve symptoms in patients with Alzheimer's and Parkinson's. As a result, more and more doctors in Europe are turning to stem cell therapy to treat neurodegenerative diseases. In the UK alone, over 700,000 people suffer from Alzheimer's, and stem cell therapy offers a glimmer of hope for these patients.
Stem Cell Therapy Market Share
The leading stem cell therapy market players include
- FUJIFILM Cellular Dynamics, Inc.
- Novadip Biosciences
- DiscGenics
- Mesoblast Ltd.
- GSK plc.
- ThermoGenesis Holdings, Inc.
- MEDIPOST Co., Ltd.
Many of these players are focusing on capacity expansion initiatives to increase their market footprint. For instance, in May 2022, Japanese multinational pharmaceutical company, Takeda Pharmaceutical Company Limited, inaugurated Ireland’s first stem cell center in Grange Castle. The facility will aid the distribution of cell therapy treatment options to patients in US, EU, and Canada.
Impact of COVID-19 Pandemic
During the COVID-19 pandemic, the stem cell therapy industry didn't take too much of a hit. In fact, there was a lot of action in this field. You see, because of COVID-19, the world was scrambling to find new ways to prevent and treat deadly diseases. This meant that scientists and governments were paying a lot of attention to stem cell research and treatments. And guess what? Stem cell therapy showed real promise in treating COVID-19 patients, especially those with severe lung problems. clinical trials popped up all over the world, finding that a type of stem cell called "mesenchymal stem cells" might be an effective way to help COVID-19 patients breathe easier. According to a website called ClinicalTrial.gov, researchers were also using these mesenchymal stem cells to figure out the best and safest treatments for COVID-19. So, the pandemic actually helped speed up the testing and development of stem cell therapies.
This stem cell therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
By Type
- Allogenic stem cell therapy
- Autologous stem cell therapy
By Therapeutic Area
- Oncology
- Orthopedic
- Cardiovascular
- Neurology
- Orthopedic
- Others
By End-use
- Hospitals
- Clinics
- Others
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Poland
- Switzerland
- Netherlands
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Singapore
- Thailand
- Latin America
- Brazil
- Argentina
- Mexico
- Chile
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Israel
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy